EVElena Lucia Valle

Elena Lucia Valle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Lucia Valle has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Gabriele Sani

    Section of Psychiatry, Department of Neuroscience, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy

    4 shared publications
  • Gianandrea Traversi

    Unit of Medical Genetics, Department of Laboratory Medicine, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy

    3 shared publications
  • Giuseppe Marano

    Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy

    3 shared publications
  • Marianna Mazza

    Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy

    3 shared publications
  • Osvaldo Mazza

    Spine Surgery Department, Bambino Gesù Children’s Hospital IRCCS, 00168 Rome, Italy

    3 shared publications
  • Caterina Brisi

    Department of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy

    2 shared publications

Latest Publications

  • Open Access

    Metabolic Signatures of Bipolar Disorder Through a Sex-Informed Lens: Emerging Biomarkers for Precision Psychiatry

    by Giuseppe Marano, Elena Lucia Valle, Oksana Di Giacomi, Gianandrea Traversi, Osvaldo Mazza, Gabriele Sani, Marianna Mazza

    Bipolar disorder (BD) is a clinically heterogeneous condition for which diagnosis, prognostic assessment, and treatment selection continue to rely predominantly on symptom-based evaluation. Metabolomics offers a promising approach to biomarker discovery by capturing the downstream effects of genetic susceptibility, environmental exposures, lifestyle, disease activity, and pharmacological treatment. Studies using peripheral biofluids, post-mortem brain tissue, and in vivo neurometabolic measures have identified alterations involving lipid metabolism, amino acids, energy production, oxidative stress, one-carbon metabolism, tryptophan–kynurenine pathways, and the gut microbiota-derived metabolome. Reproducibility is limited, and the potential influence of biological sex is frequently neglected or treated merely as a statistical covariate. This narrative review critically examines emerging metabolomic and lipidomic biomarkers in BD through a sex-informed perspective. We discuss their potential applications in differential diagnosis, mood-state characterization, illness staging, prediction of treatment response, and identification of cardiometabolic vulnerability. Particular attention is given to sex hormones, reproductive transitions, body composition, immune–metabolic regulation, circadian biology, and sex-dependent pharmacometabolic effects. Major methodological limitations, including small samples, medication exposure, inconsistent mood-state characterization, and insufficient sex-stratified validation, are also considered. Integrating sex as a biological variable into longitudinal, multi-omic, and clinically deeply phenotyped studies may improve biomarker reproducibility and support more individualized approaches to BD.

  • Open Access

    Sleep as a Transdiagnostic Target in Psychiatry: Prebiotics, the Gut–Brain Axis, and the Gap Between Mechanistic Plausibility and Clinical Evidence

    by Giuseppe Marano, Elena Lucia Valle, Giulio Carriero, Caterina Brisi, Gianandrea Traversi, Osvaldo Mazza, Gabriele Sani, Marianna Mazza

    Sleep disturbances are highly prevalent across psychiatric disorders and represent both a clinical feature and a potential transdiagnostic therapeutic target. Growing evidence suggests that the gut microbiota may contribute to sleep regulation through immune, metabolic, circadian, and neuroendocrine pathways. Prebiotics, defined as selectively utilized substrates that confer health benefits through modulation of host microorganisms, have received increasing attention as nutritional strategies capable of influencing the gut–brain axis. This narrative review summarizes preclinical and human evidence on prebiotic interventions in relation to sleep-related outcomes and psychiatric symptomatology, with particular attention to short-chain fatty acids, circadian regulation, inflammatory pathways, stress-related hypothalamic–pituitary–adrenal axis activity, and microbial metabolite signaling. Preclinical studies suggest that selected prebiotics may influence sleep architecture, stress resilience, neuroinflammation, and behavioral phenotypes, particularly under conditions of stress or sleep disruption, but translation to human populations remains preliminary. Available clinical studies are limited by small sample sizes, heterogeneous prebiotic formulations, variable doses and intervention durations, inconsistent microbiome methodologies, and frequent reliance on subjective sleep measures rather than polysomnography or actigraphy. Therefore, current evidence supports prebiotics as biologically plausible and generally well-tolerated adjunctive strategies, but not as established treatments for insomnia or psychiatric symptoms. Sleep may provide a clinically meaningful transdiagnostic framework for future nutritional psychiatry research, provided that adequately powered randomized controlled trials integrate objective sleep assessment, standardized microbiome and metabolomic profiling, and clinically relevant psychiatric outcomes.


  • Open Access

    Stratified Psychosocial Care in Assisted Reproductive Technologies: A Narrative Review and Conceptual Framework Across the IVF Pathway

    by Giuseppe Marano, Giulio Carriero, Elena Lucia Valle, Caterina Brisi, Gianandrea Traversi, Osvaldo Mazza, Claudia D’Abate, Rosanna Esposito, Gabriele Sani, Marianna Mazza

    Assisted reproductive technologies (ART), particularly in vitro fertilization (IVF), are characterized by substantial emotional burden, uncertainty, and repeated decision-making under probabilistic conditions. Although psychological distress is common among individuals and couples undergoing ART, psychosocial care remains inconsistently integrated into fertility pathways and is rarely tailored to individual needs. This narrative review synthesizes evidence concerning infertility-related distress, anxiety and depressive symptoms, couple functioning, treatment discontinuation, psychosocial screening, and psychological interventions across the IVF trajectory. Key phases of treatment, including pretreatment assessment, ovarian stimulation, embryo transfer, the waiting period, cycle outcome, and decisions regarding repetition or discontinuation, are described, and phase-specific psychological vulnerabilities are identified. On the basis of the available literature, we propose a conceptual stepped-care framework ranging from universal psychoeducation and routine monitoring to structured psychological interventions, couple-based care, and specialist psychiatric management. Practical screening thresholds, referral criteria, reassessment intervals, and a safety pathway for suicidal ideation are outlined. Particular attention is given to male-factor infertility, strategies for engaging male partners, and the ethical and data-governance requirements of digital mental health tools. Current evidence supports psychosocial interventions for improving emotional well-being and quality of life and suggests a potential role in treatment continuation, but their effects on pregnancy and live-birth outcomes remain uncertain. The proposed framework should therefore be regarded as a clinically informed conceptual model rather than a validated prediction algorithm. Prospective studies are required to assess its feasibility, predictive performance, cost-effectiveness, and impact on patient-centered outcomes.


  • Open Access

    Co-Occurrence of Avoidant/Restrictive Food Intake Disorder (ARFID) and Schizophrenia-Spectrum Disorders: A Comprehensive Review

    by Maria Benedetta Anesini, Stella Margoni, Lorenzo Moccia, Sara Barbonetti, Luca Onori, Elena Lucia Valle, Antonio Maria D’Onofrio, Francesca Focà, Mario Pinto, Georgios D. Kotzalidis, et al.

    Background/Objectives: Avoidant/restrictive food intake disorder (ARFID) and psychotic disorders are clinically distinct conditions yet occasionally co-occur in ways that complicate assessment and treatment. ARFID is characterised by avoidance of food due to sensory sensitivities, fear of aversive consequences, or low interest in eating, without body-image distortion. Recent meta-analytic evidence suggests that ARFID affects a substantial proportion of the population and is associated with a considerable social burden. Psychosis is characterised by positive symptoms (hallucinations and delusions), negative symptoms (avolition, blunted affect, and social withdrawal), and cognitive impairments affecting thought, perception, and behaviour. Methods: Across the limited literature, shared mechanisms between ARFID and psychotic disorders appear to converge on pathological avoidance, which may arise from sensory overstimulation, obsessive–compulsive features, or delusional beliefs about food. Case reports indicate that psychosis may both mimic ARFID and exacerbate food avoidance, while severe malnutrition can itself precipitate or worsen psychotic symptoms, blurring diagnostic boundaries. Results: Abnormalities in interoception, sensory sensitivity, and disrupted perception of bodily signals are manifestations of both ARFID and psychosis, suggesting a potential bridging pathway contributing to vulnerability and clinical overlap. Conclusions: Given the paucity of empirical studies and the reliance on isolated case reports, systematic investigation is mandatory and necessary to clarify shared mechanisms, refine differential diagnosis, and guide integrated treatment approaches. Given the heterogeneity of symptoms in comorbid patients, a personalised approach is suggested for treating these patients.